What is William Blair’s Estimate for BRNS FY2024 Earnings?

Barinthus Biotherapeutics plc (NASDAQ:BRNS) – Analysts at William Blair raised their FY2024 EPS estimates for Barinthus Biotherapeutics in a note issued to investors on Wednesday, November 6th. William Blair analyst A. Hsieh now anticipates that the company will post earnings of ($1.44) per share for the year, up from their previous estimate of ($1.59). The consensus estimate for Barinthus Biotherapeutics’ current full-year earnings is ($1.63) per share. William Blair also issued estimates for Barinthus Biotherapeutics’ Q4 2024 earnings at ($0.40) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.52) EPS and FY2026 earnings at ($1.70) EPS.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.23. The company had revenue of $14.97 million for the quarter. During the same period in the prior year, the company posted ($0.37) EPS.

BRNS has been the topic of a number of other reports. Alliance Global Partners decreased their target price on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Barinthus Biotherapeutics in a research note on Friday, November 8th.

Barinthus Biotherapeutics Price Performance

Shares of NASDAQ:BRNS opened at $1.40 on Monday. Barinthus Biotherapeutics has a 1 year low of $1.11 and a 1 year high of $4.16. The firm has a market capitalization of $56.32 million, a PE ratio of -0.92 and a beta of -0.59. The business’s 50 day moving average price is $1.29 and its 200-day moving average price is $1.55.

Institutional Trading of Barinthus Biotherapeutics

A number of large investors have recently made changes to their positions in BRNS. M&G Plc acquired a new position in Barinthus Biotherapeutics during the 2nd quarter worth approximately $7,276,000. Alphabet Inc. purchased a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter worth $2,119,000. DC Funds LP purchased a new position in Barinthus Biotherapeutics in the first quarter valued at $1,528,000. BlueCrest Capital Management Ltd purchased a new position in Barinthus Biotherapeutics in the first quarter valued at $1,292,000. Finally, Ipswich Investment Management Co. Inc. acquired a new stake in Barinthus Biotherapeutics in the second quarter valued at $32,000. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.